Bisphosphonates inhibit the mevalonate pathway in osteoclasts, inducing their apoptosis, leading to inhibition of bone resorption. Additionally, the drugs open Cx43 hemichannels, promoting survival of osteocytes and osteoblasts, maintaining bone strength and bone formation.